NervGen Pharma Corp.
corporate_fare Company Profile
NervGen Pharma Corp. (NASDAQ:NGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-25, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NGEN spans 6-K, F-10, 40-F.
Recent high-impact activity:
- NervGen to Restate Financials on Non-Cash Accounting Adjustments
- NervGen Pharma Restates FY2024–FY2025 and Q2 2026 Financials Over Non-Cash Valuation Errors
- NervGen Posts C$0.32 Q2 Loss as Warrant Charge Hits Bottom Line
- NervGen Q2 Loss Widens on Warrant Charge; Phase 3 RESTORE Screening Set for September
- NervGen Pharma Establishes $50M At-The-Market Equity Program
Financial Snapshot
Short Interest & Short Volume
10.44 days to coverFINRA reported short interest of 5,489,865 shares in NGEN as of the September 15, 2026 settlement, a 0.8% increase from the prior period — about 10.4 days to cover at its recent average daily volume. On October 2, 2026, 71.0% of NGEN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NGEN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
New ATM Program Established · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NGEN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.